((自动化翻译由路透提供，请见免责声明 ))
路透9月17日 - 据彭博新闻社周二援引一位公司高管的话报导，丹麦制药商诺和诺德 预计其糖尿病药物Ozempic "极有可能 "被列入美国政府2027年的价格谈判名单 (link)。
2022年《通胀削减法》（Inflation Reduction Act）的部分条款允许联邦医疗保险（Medicare）对价格特别昂贵的处方药进行价格谈判 (link)，该联邦医疗保险覆盖了数百万65岁及以上的美国人和残疾人。
诺和诺德的高管此前曾表示，现在要知道谈判对Ozempic的影响还为时过早。华尔街分析师还押注于2027年上市的 (link)，其中将包括Ozempic。
该公司没有立即回应路透的置评请求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.